Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Literature DB >> 23773898

Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Eyal C Attar¹, Philip C Amrein, James W Fraser, Amir T Fathi, Steven McAfee, Martha Wadleigh, Daniel J Deangelo, David P Steensma, Richard M Stone, Julia Foster, Donna Neuberg, Karen K Ballen.

Abstract

We conducted a phase I dose escalation study to determine the maximal tolerated dose of bortezomib that could be combined with standard dose lenalidomide in patients with MDS or AML. Treatment consisted of bortezomib (IV) on Days 1, 4, 8, and 11 and lenalidomide 10mg daily (PO) days 1-21 in 28 day cycles for up to 9 cycles. 23 patients (14 MDS/CMML, 9 AML) were enrolled. The maximally tested dose of bortezomib, 1.3mg/m(2), was tolerable in this regimen. Responses were seen in patients with MDS and AML. Further testing of this regimen is planned.

Entities: Chemical Disease Gene Species

Keywords: Bortezomib and lenalidomide in MDS and AML

Mesh：

Substances：

Year: 2013 PMID： 23773898 PMCID： PMC3969839 DOI： 10.1016/j.leukres.2013.05.011

Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156

18 in total

1. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Authors: Paul G Richardson; Edie Weller; Sagar Lonial; Andrzej J Jakubowiak; Sundar Jagannath; Noopur S Raje; David E Avigan; Wanling Xie; Irene M Ghobrial; Robert L Schlossman; Amitabha Mazumder; Nikhil C Munshi; David H Vesole; Robin Joyce; Jonathan L Kaufman; Deborah Doss; Diane L Warren; Laura E Lunde; Sarah Kaster; Carol Delaney; Teru Hideshima; Constantine S Mitsiades; Robert Knight; Dixie-Lee Esseltine; Kenneth C Anderson
Journal: Blood Date: 2010-04-12 Impact factor: 22.113

2. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors: Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245

3. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

Authors: Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian
Journal: Blood Date: 2006-04-11 Impact factor: 22.113

4. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells.

Authors: M L Guzman; S J Neering; D Upchurch; B Grimes; D S Howard; D A Rizzieri; S M Luger; C T Jordan
Journal: Blood Date: 2001-10-15 Impact factor: 22.113

5. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome.

Authors: Thorsten Braun; Gabrielle Carvalho; Arnaud Coquelle; Marie-Catherine Vozenin; Pascale Lepelley; François Hirsch; Jean-Jacques Kiladjian; Vincent Ribrag; Pierre Fenaux; Guido Kroemer
Journal: Blood Date: 2005-10-13 Impact factor: 22.113

6. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.

Authors: Paul G Richardson; Edie Weller; Sundar Jagannath; David E Avigan; Melissa Alsina; Robert L Schlossman; Amitabha Mazumder; Nikhil C Munshi; Irene M Ghobrial; Deborah Doss; Diane L Warren; Laura E Lunde; Mary McKenney; Carol Delaney; Constantine S Mitsiades; Teru Hideshima; William Dalton; Robert Knight; Dixie-Lee Esseltine; Kenneth C Anderson
Journal: J Clin Oncol Date: 2009-09-28 Impact factor: 44.544

7. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Authors: Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Journal: J Clin Oncol Date: 2003-12-15 Impact factor: 44.544

8. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Authors: Azra Raza; James A Reeves; Eric J Feldman; Gordon W Dewald; John M Bennett; H Joachim Deeg; Luke Dreisbach; Charles A Schiffer; Richard M Stone; Peter L Greenberg; Peter T Curtin; Virginia M Klimek; Jamile M Shammo; Deborah Thomas; Robert D Knight; Michele Schmidt; Kenton Wride; Jerome B Zeldis; Alan F List
Journal: Blood Date: 2007-09-24 Impact factor: 22.113

9. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.

Authors: Eyal C Attar; Jeffrey L Johnson; Philip C Amrein; Gerard Lozanski; Martha Wadleigh; Daniel J DeAngelo; Jonathan E Kolitz; Bayard L Powell; Peter Voorhees; Eunice S Wang; William Blum; Richard M Stone; Guido Marcucci; Clara D Bloomfield; Barry Moser; Richard A Larson
Journal: J Clin Oncol Date: 2012-11-05 Impact factor: 44.544

10. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.

Authors: Eyal C Attar; Daniel J De Angelo; Jeffrey G Supko; Ferdinando D'Amato; David Zahrieh; Andres Sirulnik; Martha Wadleigh; Karen K Ballen; Steve McAfee; Kenneth B Miller; James Levine; Ilene Galinsky; Elizabeth G Trehu; David Schenkein; Donna Neuberg; Richard M Stone; Philip C Amrein
Journal: Clin Cancer Res Date: 2008-03-01 Impact factor: 12.531

14 in total

Review 1. Epigenetics in myelodysplastic syndromes.

Authors: Michael Heuser; Haiyang Yun; Felicitas Thol
Journal: Semin Cancer Biol Date: 2017-08-02 Impact factor: 15.707

Review 2. NF-κB signaling in cancer stem cells: a promising therapeutic target?

Authors: K Vazquez-Santillan; J Melendez-Zajgla; L Jimenez-Hernandez; G Martínez-Ruiz; V Maldonado
Journal: Cell Oncol (Dordr) Date: 2015-08-29 Impact factor: 6.730

Review 3. Proteasome inhibitors in cancer therapy.

Authors: Elisabet E Manasanch; Robert Z Orlowski
Journal: Nat Rev Clin Oncol Date: 2017-01-24 Impact factor: 66.675

4. A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia.

Authors: Daniel J DeAngelo; Andrew M Brunner; Lillian Werner; David Avigan; Amir T Fathi; Adam S Sperling; Abigail Washington; Dina Stroopinsky; Jacalyn Rosenblatt; Malgorzata McMasters; Katarina Luptakova; Martha Wadleigh; David P Steensma; Gabriela S Hobbs; Eyal C Attar; Philip C Amrein; Benjamin L Ebert; Richard M Stone; Karen K Ballen
Journal: Am J Hematol Date: 2017-11-21 Impact factor: 10.047

Review 5. Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

Authors: Amir T Fathi; Yi-Bin Chen
Journal: Curr Hematol Malig Rep Date: 2014-06 Impact factor: 3.952

Review 6. Expanding role of lenalidomide in hematologic malignancies.

Authors: Nilanjan Ghosh; Michael R Grunwald; Omotayo Fasan; Manisha Bhutani
Journal: Cancer Manag Res Date: 2015-05-02 Impact factor: 3.989

Review 7. Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target.

Authors: Jianbiao Zhou; Ying Qing Ching; Wee-Joo Chng
Journal: Oncotarget Date: 2015-03-20